Identification of Biomarkers for Prediction of Hepatocellular Carcinoma after Elimination of Hepatitis C Virus by Antiviral Medicines, Elbasvir and Grazoprevir
Not Applicable
- Conditions
- Chronic hepaititis due to HCV Compensated liver cirroshis due to HCV
- Registration Number
- JPRN-UMIN000025575
- Lead Sponsor
- Kanazawa University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with a history of hypersensitivity to any of the ingredients of Elbasvir/Grazoprevir(CONTRAINDICATIONS in the package insert) 2)Patients who are using any of contraindicated co-medications listed in the package insert 4)Patients with moderate or severe liver dysfunction (Child-Pugh classification B or C) 5)Patients who have received treatment for HCC within the past 24 weeks
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method